Literature DB >> 10521073

Tamoxifen-induced thrombocytopenia.

J C Yao1, N Thomakos, P McLaughlin, T A Buchholz, A P Kudelka.   

Abstract

Thrombocytopenia (platelet count < 100,000/microl) is a rare side effect of tamoxifen (Nolvadex). We report a case of thrombocytopenia that developed 6 months after tamoxifen was given as an adjuvant treatment for breast cancer. The patient received no concurrent cytotoxic chemotherapy or radiation therapy. The thrombocytopenia resolved after the tamoxifen was stopped, reappeared promptly when the tamoxifen was restarted, and resolved again after the second withdrawal, at which time anastrozole (Arimidex) was substituted for the tamoxifen. The patient's platelet count remained normal for more than 6 months thereafter.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10521073     DOI: 10.1097/00000421-199910000-00022

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  2 in total

Review 1.  Drug-induced immune thrombocytopenia.

Authors:  Patricia M L A van den Bemt; Ronald H B Meyboom; Antoine C G Egberts
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

2.  Tamoxifen induced-thrombocytopenia: it does occur.

Authors:  Narin Nasiroğlu; Merve Pamukçuoğlu; Hüseyin Abali; Berna Oksüzoğlu; Ayşegül Uner; Nurullah Zengin
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.